GeneDx Holdings Corp.
NASDAQ Global MarketCapital Structure
•
in mil. unless spec.Working Capital
•
in mil. unless spec.Growth Rates
•
in mil. unless spec.Quarterly Revenue
•
in mil. unless spec.Quarterly Earnings Per Share
•
in mil. unless spec.Quarterly Dividends Per Share
•
in mil. unless spec.- CEO
- Katherine A. Stueland
- Full Time Employees
- 1,300
- Sector
- Healthcare
- Industry
- Medical - Healthcare Information Services
- Address
- North Tower Stamford CT United States of America 06902
- IPO Date
- Nov 4, 2020
- CIK
- 0001818331
- Website
- genedx.com
- Similar Companies
- Business
- GeneDx Holdings Corp. operates as a genetic testing and genomic information company specializing in clinical genetic testing services and genomic diagnostics. It offers a comprehensive range of products and services including hereditary disease testing, rare and ultra-rare disease diagnostics, prenatal genetic testing, oncology-related genetic analysis, carrier screening, pharmacogenomics, and whole exome and genome sequencing assays. The company addresses clinical needs through specialized genetic tests, interpretation services, and advanced genomic data analysis primarily for healthcare providers, researchers, and pharmaceutical companies. Headquartered in Gaithersburg, Maryland, and founded in 2000, GeneDx serves a broad geographic market including the United States and international locations. Recent major company developments include strategic expansions in partnerships and service offerings to enhance precision medicine capabilities, with a focus on expanding its testing panels and integrating advanced bioinformatics tools. GeneDx has made significant strides in developing new genetic tests tailored for rare diseases and oncology, reflecting a strategic emphasis on personalized medicine and broader clinical application. These advancements are alongside ongoing investments in research and development to support novel diagnostic solutions. GeneDx is positioned within the molecular diagnostics and genomics industry, targeting clinicians, hospitals, research institutions, and biopharmaceutical firms. It is part of a growing sector driven by advances in genetic sequencing technologies and the increasing demand for personalized healthcare solutions. This detailed profile encapsulates GeneDx’s core business activities, product portfolio, recent strategic initiatives, industry context, and market focus, reflecting its role as a leading provider of genomic testing services.
WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit with the Schall Law Firm
WGS Shareholder Alert: GeneDx Holdings Corp. Securities Class Action Lawsuit - Investors Should Contact Levi & Korsinsky
HBSS Investigates Claims Against GeneDx Holdings (WGS) in Securities Class Action Suit Following Massive Impairment Charge
WGS DEADLINE: ROSEN, HIGHLY RECOGNIZED INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS
WGS CLASS ACTION NOTICE: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
Bronstein, Gewirtz & Grossman LLC Urges GeneDx Holdings Corp. Investors to Act: Class Action Filed Alleging Investor Harm
Thrivent Small Cap Growth Fund Q2 2026 Portfolio Review
WGS DEADLINE: ROSEN, A TOP-RANKED LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS
GeneDx Holdings Corp. (WGS) Investors: August 3, 2026, Filing Deadline in Securities Fraud Class Action - Contact Kessler Topaz Meltzer & Check, LLP
WGS Deadline: WGS Investors Have Opportunity to Lead GeneDx Holdings Corp. Securities Fraud Lawsuit
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors may Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
WGS DEADLINE: ROSEN, A LEADING LAW FIRM, Encourages GeneDx Holdings Corp. Investors to Secure Counsel Before Important Deadline in Securities Class Action - WGS
GeneDx Holdings Securities Fraud Class Action Result of Acquisition Performance Misrepresentations and 49% Stock Decline - Investors May Contact Lewis Kahn, Esq, at Kahn Swick & Foti, LLC
WGS DEADLINE ALERT: Faruqi & Faruqi, LLP Reminds GeneDx (WGS) Investors of Securities Class Action Lawsuit Deadline on August 3, 2026
GeneDx Holdings (WGS) Hit with Securities Class Action Following 49% Stock Collapse — HBSS
GeneDx Holdings (WGS) Hit with Securities Class Action Following 49% Stock Collapse — HBSS
WGS Shareholder Alert: Investors With Losses May Seek to Lead the Class Action in GeneDx Holdings Corp. Securities Lawsuit - Contact The Gross Law Firm
ROSEN, GLOBAL INVESTOR COUNSEL, Encourages GeneDx Holdings Corp. Investors with Losses in Excess of $100K to Secure Counsel Before Important Deadline in Securities Class Action - WGS
GeneDx to Report Second Quarter 2026 Financial Results on Monday, August 3, 2026
WGS DEADLINE ALERT: Robbins Geller Rudman & Dowd LLP Announces that GeneDx Holdings Corp. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - August 3, 2026 Deadline